Candida Parapsilosis
US-FDASourced from openFDA
GET
/api/v1/drug/candida-parapsilosisIndications
Sourced from openFDA- This remedy is indicated for symptoms that afflict body orifices including mycotic infections, leucorrhea, dental foci, granuloma dentis, rhagades and pernphigus according to traditional homeopathic practice.*
Dosage & administration
Sourced from openFDADIRECTIONS: Take 5 – 10 drops orally, three times per day.
Warnings & precautions
Sourced from openFDADo not use if the tamper evident strip is broken or removed from the base of the cap.
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
1 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Cardiac Flutter1100%
- 2Heart Rate Increased1100%
- 3Palpitations1100%
- 4Product Substitution Issue1100%
- 5Supraventricular Extrasystoles1100%
- 6Ventricular Extrasystoles1100%
- 7Wrong Technique In Drug Usage Process1100%
Literature
Recent PubMed references pinned to Candida Parapsilosis as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Surface Carrier Testing of Hospital Antiseptics Against Candida parapsilosis from Healthcare Workers' Hands.Pathogens (Basel, Switzerland) · 2026 · Belizário JA, Jardine MEB, Pereira GL, et al.PMID 42075737DOI 10.3390/pathogens15040410
- Six-month surveillance of Candida parapsilosis in Tyrol, Austria: high-risk ST11 lineage and early, heterogeneous fluconazole resistance.Frontiers in cellular and infection microbiology · 2026 · Steixner S, Vahedi-Shahandashti R, Eisele D, et al.PMID 41982454DOI 10.3389/fcimb.2026.1771561
- Targeted treatment of oral candidiasis caused by Candida albicans and Candida parapsilosis using diosmetin: A phytotherapeutic approach in dentistry.Archives of oral biology · 2026 · Gunasekaran V, Shirin F, Pujakrishna GS, et al.PMID 41966614DOI 10.1016/j.archoralbio.2026.106596
- We Are Family: Comparative Study of Candida Species and Candidozyma auris in Laundry (EN 17658) and Surface (Biofilm) Disinfection.Pathogens (Basel, Switzerland) · 2026 · Brands B, van Leuven N, Bockmühl D, et al.PMID 41901766DOI 10.3390/pathogens15030313
- Genomic Characterization of Candida spp. Highlights a Persistent, Azole-Resistant C. parapsilosis Clone Circulating in a Tertiary Care Hospital During the First COVID-19 Wave.Mycopathologia · 2026 · Vumbaca M, Batisti Biffignandi G, Cavanna C, et al.PMID 41840233DOI 10.1007/s11046-026-01070-9
- Azole Resistance in Candida parapsilosis From Patients With Burns in Mexico: A Genomic and Phylogenetic Analysis.Mycoses · 2026 · García-Hernández ML, Nuñez-García LÁ, Ortíz-Álvarez J, et al.PMID 41793231DOI 10.1111/myc.70161
- First Report of Fluconazole-Resistant Candida parapsilosis Harbouring the G458S ERG11p Substitution in a Brazilian Hospital.Mycoses · 2026 · Gonçalves SS, Maifrede SB, Yäkel E, et al.PMID 41778526DOI 10.1111/myc.70160
- Persistence and spread of fluconazole-resistant Candida parapsilosis clinical isolates associated with increased ERG11 copies in Qatar.Microbial genomics · 2026 · Zhang Z, Wang Y, Ben Abid F, et al.PMID 41719169DOI 10.1099/mgen.0.001653
Clinical trials
The 2 most recently updated of 2 ClinicalTrials.gov registrations naming Candida Parapsilosis as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Retrospective Chart Review of Candida FungemiaCompleted · Observational · 75 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)NCT03827330updated 2020-11-27
- Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive CandidiasisCompleted · Phase 4 · Interventional · 282 enrolled · PfizerNCT00496197updated 2011-10-03
Frequently asked questions
- What is Candida Parapsilosis used for?
- According to FDA labeling, Candida Parapsilosis carries indications including: This remedy is indicated for symptoms that afflict body orifices including mycotic infections, leucorrhea, dental foci, granuloma dentis, rhagades and pernphigus according to traditional homeopathic practice.*. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
Note. Data for
candida-parapsilosis is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.